Oncology drug expenditure governance in an antineoplastic drug unit: comparative economic analysis 2023–2025 and the stratified recovery rate
Introduction: Direct hospital pharmaceutical expenditure in Italy grew by +6.0% in 2025. Antineoplastic Drug Units (ADUs) play a key governance role through AIFA registry management, managed entry agreement (MEA) recovery, and prescribing appropriateness monitoring. No standardized indicator distinguishes recoveries dependent on local activity from those determined nationally.Methods: Retrospective three-year comparative economic analysis, 2023-2025, at the ADU of a local health authority in southern Italy (~540,000 inhabitants). Expenditure, patient volumes, preparation counts, and recoveries were extracted from the AIFA registry platform and ADU management system. Recoveries were stratified into Tier 1 (national: AIFA MEA rebates, Innovative Drug Fund receipts) and Tier 2 (local: Law 648/96 recoveries, trial and compassionate use cost avoidance). Gross (all recoveries over net expenditure) and Local (Tier 2 over net expenditure) Recovery Rates were calculated.Results: Net expenditure grew +8.0% in 2023, +19.0% in 2024 and +3.86% in 2025, below the +6.0% national growth, despite a +19.2% increase in treated patients (3,341 vs 2,804) and +21.8% in preparations. Cost per patient decreased from €11,286 to €9,837 (−12.8%). Total recoveries were €5,261,136, €5,291,062, and €8,918,159. The Gross Recovery Rate was 19.8%, 16.7%, and 27.1%; the Local Recovery Rate was 6.7%, 4.7%, and 6.5%.Conclusions: The ADU governance model was associated with simultaneous expansion of patient access and reduction of per-patient cost. The stratified Recovery Rate separates recoveries dependent on local activity from those determined nationally, offering a transparent, reproducible indicator for benchmarking ADU governance across Italian NHS settings and European health systems with national MEA frameworks.
Authors
- Vito Gregorio Colacicco
- Alessandro Maggi (ORCID: https://orcid.org/0009-0001-1666-646X)
- Salvatore Pisconti (ORCID: https://orcid.org/0000-0002-1658-523X)
- Francesco Colasuonno
- Tiziana Guarino (ORCID: https://orcid.org/0009-0000-4956-2926)
- Antonio Ungaro (ORCID: https://orcid.org/0000-0003-0548-2611)
- Filomena D'Amico (ORCID: https://orcid.org/0009-0000-7330-8215)
- Loredana Brandi (ORCID: https://orcid.org/0009-0006-9007-8654)
- Viviana Bruno (ORCID: https://orcid.org/0009-0009-8358-9482)
Publication Details
- Journal
- Global & Regional Health Technology Assessment
- Published
- 2026-11-17
- DOI
- https://doi.org/10.33393/grhta.2026.3970
- Primary Topic
- Pharmaceutical Economics and Policy
- Type
- article
- Field-Weighted Citation Impact
- 0.00